202 results about "Pharmacological therapy" patented technology

Process and device for directly medicinally treating interior tissue during or after intubation of a patient by passing medicinal radiant energy transversely through the intubation device to irradiate the internal patient tissue for promoting healing or for an antimicrobial effect. The invention is useful in conjunction with endoscopies and catherizations, such as urinary catherization, gastric and pulmonary endoscopies, and the like procedures. The process and device can also provide liquid flow and/or vision.

The invention relates to a body and mind health care system with musical and color light physical factors based on three networks and the internet of things, which combines body physical therapy by physiotherapy (a body treating function), psychotherapy by music therapy (a mind treating function) and traditional Chinese channel and point therapy (a root treating function), and adds chromophototherapy in the therapy of environmental parameters, thereby achieving treatment of body, mind and root, embodying a new biological, psychological and social medical mode, and realizing a brand-new non-pharmacotherapy mode. A positioning technology and an internet technology are combined for establishing a medical care network system conveniently; a biological information sensor is used so that the system can detect the therapy effect instantly; an environmental parameter sensor is used for building the activation environment of system users into a scientific environment; and multiple physical factors are collected into one physiotherapy function module, so that one or more physical factors can be selected simultaneously for therapy to ensure the therapeutic effect. A biological information detecting/environmental monitoring module, the internet technology and a multipath camera/microphone of the system can be used for realizing remote monitoring.

The invention relates generally to a pharmacological therapy for a human genetic diseases, specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxyribonucleoside monophosphate, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine monophosphate (dTMP) or deoxycytidine monophosphate (dCMP), or mixtures thereof. This molecular bypass approach is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.

Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.

The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying biomarkers, the expression of which correlates to treatment sensitivity or resistance within a patient population or subpopulation.

A resorbable, biodegradable, drug delivery prosthesis (10) includes mechanical properties for maintaining the strength needed to acutely open and maintain a vessel, duct, tract, or organ, and precise chronicity for controlling the release and delivery of drugs or biologic agents. The drugs and biologic agents are capable of acting upon and altering the mechanisms of biologic systems in an manner providing a medicinal therapy. The method of the invention includes a one step process of extruding the admixture forming the prosthesis (10) into a geometry compatible with its use.

The invention discloses a relevant gene combination, a primer, a probe and application used for detecting a chemotherapeutic effect on acute myelogenous leukemia. The gene combination comprises four gene combinations closely relevant to pharmacotherapy of the acute myelogenous leukemia: medicament metabolism phase I enzyme gene CYP3A5, medicament metabolism phase II enzyme genes NAT2 and GSTO2, and medicament transport protein gene OATP1B1; and the gene combination comprises the following SNP loci: the locus rs776746 of the gene CYP3A5, the locus rs1799931 of the gene NAT2, the locus rs156697 of the gene GSTO2, and the locus rs4149056 of the gene OATP1B1. A method is performed by hybridizing a specific primer and probes which are subjected to fluorescence marks of different colors with target gene fragments in a nucleic acid sample after PCR amplification. The treatment effect of a leukemia medicament is detected and analyzed by mononucleotide extension technology so as to direct clinical medicament application, reduce a toxic or side effect of the medicament application for a patient, and increase a curative effect.

The invention provides a multifunctional nano-drug combination and a preparation method thereof. The combination comprises a carrier and active ingredients loaded on the carrier, wherein the carrier is a polymer formed by mPEG-PLGA and/or PEG-PLGA and a porphyrin compound through covalent-bond connection, and the active ingredients include hydrophobic and hydrophilic drugs. Preferentially, the carrier and the active ingredients loaded on the carrier form particles with the nano size of 50-1000 nm. The multifunctional nano-drug combination has photo-thermal effect so that the treatment efficiency can be improved based on traditional chemotherapy in combination with photo-thermal therapy, and the multifunctional nano-drug combination can be applied to cancer therapy drugs.

Disclosed are inhibitors of the USP1/UAF1 deubiquitinase complex, for example. of formula (I), wherein R¹, R², and Q are as defined herein, which are useful in treating diseases such as cancer, and improving the efficacy of DNA damaging agents in cancer treatment. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a heterodimeric deubiquitinase complex in a cell, and a method of enhancing the chemotherapeutic treatment of cancer in a mammal undergoing treatment with an anti cancer agent. Further disclosed is a method of preparing compounds of the invention.

The present disclosure relates to HLA-E as a tumor escape mechanism in head and neck cancer. The disclosure relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.

The invention relates to a new mutant protein related to dilated cardiomyopathy, a new mutant gene and application thereof, discloses a mutant protein and a mutant TTN gene, has c.20292-20293 heterozygosis deletion variation compared with a human TTN gene, verifies that the mutation is related to dilated cardiomyopathy through research data, and protects the mutant protein and the gene based on arequest. And a kit for detecting dilated cardiomyopathy is disclosed. The mutant TTN gene provided by the invention can distinguish patients with dilated cardiomyopathy from normal people, and can beused as a biomarker for clinical auxiliary diagnosis of dilated cardiomyopathy. Carriers of the variation can be screened in the early stage, and prenatal and postnatal guidance and genetic counselingare provided for subjects. And a possible drug treatment target is provided for human to overcome the dilated cardiomyopathy.

An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, or TLR4-FLNA and/or α7nAChR-Aβ₄₂ complex present as a protein-protein complex in a sample is compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is compared to an amount in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four pharmacophores of FIGS. 7-12. An amount of protein or protein complex determined in the presence of medicament that is less than the first amount indicates a favorable treatment prognosis.

The invention provides a gold nanoparticle complex with an effect of inhibiting nerve cell apoptosis and an application thereof. The gold nanoparticle complex is prepared by the following steps: modifying thiolated chitosan (TCTS) onto the surface of gold nanoparticles, performing electrostatic adsorption on pDNA interfering alpha-synuclein synthesis, finally grafting a nerve growth factor by adopting a photo-grafting method, thereby obtaining the complex. The successfully synthesized gold nanoparticle complex acts on nerve cells, the cell apoptosis can be obviously inhibited by the complex, and the complex has an effect of inhibiting apoptosis of an in-vitro cell model for Parkinson's disease, is a method and novel drug for treating the Parkinson's disease occurring after operative treatment and chemotherapy and has high guiding significance for treating and researching the disease.

The invention provides a preparation method for a mouse thrombotic stroke model. The method comprises the following steps: after anesthetizing a mouse, making a slipknot on a common carotid artery byusing a suture line, and separating and permanently ligating an external carotid artery and a pterygopalatine artery; separating the initial part of an internal carotid artery; putting the common carotid artery into a groove of a blood vessel electric shock clip of a thrombus generator, and carrying out electrical stimulation to form a thrombus; taking off the electric shock clip and clipping thedistal end of the common carotid artery; crushing the thrombus by using a pair of microscope forceps, enabling the artery to pulsate again, and impacting and crushing the thrombus; releasing an arteryclip; after expelling the thrombus to enter the internal carotid artery by using the forceps, immediately closing the proximal end of the common carotid artery; and opening all artery clips after pre-set time, so as to form a target thrombus model. The mouse thrombotic stroke model provided by the invention can be applied to researches of treatment medicines and methods for stroke, and pathogenesis.